Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

329.20
-0.1500-0.05%
Volume:325.49K
Turnover:107.15M
Market Cap:43.49B
PE:141.29
High:332.15
Open:329.23
Low:324.48
Close:329.35
52wk High:495.55
52wk Low:205.87
Shares:132.11M
Float Shares:126.15M
Volume Ratio:0.45
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.33
EPS(LYR):2.33
ROE:73.28%
ROA:6.81%
PB:55.11
PE(LYR):141.29

Loading ...

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Reuters
·
Feb 23

Assessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth

Simply Wall St.
·
Feb 20

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2026-02-19

Reuters
·
Feb 20

Alnylam Pharmaceuticals Price Target Maintained With a $510.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 19

Tarsus Pharmaceuticals Names Former Allergan CEO David Pyott to Board

Reuters
·
Feb 18

Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise

Simply Wall St.
·
Feb 18

Alnylam CFO Jeffrey V. Poulton Reports Sale of Common Shares

Reuters
·
Feb 18

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-02-17

Reuters
·
Feb 18

Stock Track | Alnylam Pharmaceuticals Soars 5.28% Intraday on Positive Analyst Ratings

Stock Track
·
Feb 17

Alnylam Pharmaceuticals Raised to Buy From Hold by Freedom Capital Markets

Dow Jones
·
Feb 17

Canaccord Genuity Keeps Their Buy Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
Feb 17

Alnylam Pharma (ALNY) Receives a Buy from Barclays

TIPRANKS
·
Feb 17

Alnylam upgraded to Buy from Hold at Freedom Capital

TIPRANKS
·
Feb 17

Cantor Fitzgerald Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

TIPRANKS
·
Feb 15

Alnylam Pharmaceuticals (ALNY) Turns Profitable With Q4 EPS Of US$1.41 Challenging Bearish Narratives

Simply Wall St.
·
Feb 15

Alnylam price target lowered to $360 from $408 at Morgan Stanley

TIPRANKS
·
Feb 13

RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating

MT Newswires Live
·
Feb 13

Alnylam Pharmaceuticals Inc : Raymond James Cuts Target Price to $420 From $472

THOMSON REUTERS
·
Feb 13

U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections

Reuters
·
Feb 13

Alnylam Pharmaceuticals Inc : Chardan Capital Markets Cuts Target Price to $425 From $475

THOMSON REUTERS
·
Feb 13